Clinical Trials

The latest from Cogstate, leaders in optimizing the measurement of cognition

Cogstate and Clinical Ink Deliver Enhanced Tablet-Based eCOA for CNS Clinical Trials

October 24, 2016

New Haven, CT & Philadelphia, PA– October 25, 2016: Cognitive science company, Cogstate Ltd (ASX.CGS) and Clinical Ink, the leading provider of eSource and patient engagement technologies, today announced they have formalized their long-standing relationship with a strategic alliance that delivers enhanced tablet-based neuropsychological assessments for CNS clinical trials. The alliance combines, in a single […]

Study Finds Cogstate Computerized Tests Effective In Unsupervised Setting

December 15, 2015

One longstanding limitation to large scale assessment of cognition has been the need to bring people to testing locations, so that pencil and paper tests can be administered, supervised and scored by a trained proctor. Alternatively, trained proctors may visit people in their homes to conduct assessments. Either way, the requirement for supervised assessment of […]

Measuring The Rate Of Adolescent Cognitive Development In 38,778 Individuals

October 20, 2015

Decades of research on cognitive development and change have given neuroscientists volumes of data on the adult brain to better understand abnormalities and pursue treatments for a variety of neurodegenerative diseases. Of course, every adult brain was once an adolescent brain developing at its own unique pace. Surprisingly, much less is known about this early […]

New Study Links Rilapladib To Cognitive Improvement

September 13, 2015

“The finding that rilapladib improved cognition in this group is very exciting” In a much anticipated research update, GlaxoSmithKline (GSK) has released the results of a two-year study of rilapladib as a possible treatment for dementia. Using tests for executive function and working memory from Cogstate, GSK researchers were able to observe cognitive improvement in […]

COGSTATE RELEASES LATEST VERSION OF ONLINE COGNITIVE SCREENING SOLUTION FOR CLINICAL TRIALS: PRECISION RECRUITMENT

July 28, 2015

ADDRESSING THE MOUNTING CHALLENGE OF PATIENT RECRUITMENT IN ALZHEIMER’S DISEASE CLINICAL TRIALS AND OTHER HIGH-NEED INDICATIONS Melbourne, Australia – 22 July 2015: Cogstate Ltd (ASX.CGS), a cognitive science and medical technology company, today announced the latest version of its remote cognitive assessment solution for pre-screening participants in clinical trials, Precision Recruitment™ 2.1. Precision Recruitment™ supports […]

Cogstate Cognition Technology Featured At AAIC 2014

July 8, 2014

At the Alzheimer’s Association International Conference (AAIC) in Copenhagen next week, thousands of the leading researchers from 60 countries will provide an update on the latest theories, therapeutics and progress in the global fight against dementia diseases.  Cogstate will be well represented at the conference with poster and panel presentations that describe how our cognition […]

Antidepressant Vortioxetine Shown To Improve Cognitive Function

June 17, 2014

In addition to the more well known emotional symptoms of depression, such as a lack of interest, low self-esteem and hopelessness, patients can also suffer from cognitive problems including memory loss, attention and poor decision making.  Finding medical treatments that can manage both sets of conditions has been difficult but a new study from Danish […]

Cogstate Tests Show Cognitive Preservation In Multiple Sclerosis Patients

May 22, 2014

Of the many challenges that face adults with Multiple Sclerosis (MS), the deterioration of their cognitive function is often the most debilitating. Problems with memory, information processing and everyday decision-making are consequences of the neural communication breakdown caused by the loss of the myelin sheath insulation protecting each neuron. Finding treatment options that can slow […]

Young Cancer Patients Benefit From Computerized Cognition Testing

April 24, 2014

One of the unfortunate side effects for children being treated for cancer is a decline in neurocognitive abilities, including attention, working memory and executive function.  These changes need to be monitored throughout the course of the disease and its treatment. Traditional cognition tests using paper and pencil are difficult for children to complete, as they […]

Turning Back The Clock On Alzheimer’s Disease – Cogstate And The A4 Study

March 24, 2014

Researchers are trying to get ahead of the Alzheimer’s disease (AD) diagnostic curve by looking for ways to identify, and potentially treat, its underlying causes long before cognitive decline begins to emerge. One target in this search is the presence of amyloid deposits in the brain, a form of plaque that is thought to disrupt […]

Two New Alzheimer’s Disease Studies Show Sensitivity Of Cogstate Tests

March 10, 2014

Every month brings new research support for the central role that beta-amyloid (Aβ) plaques play in the progression of Alzheimer’s disease in the human brain.  Breaking off of a larger protein from the membrane surrounding nerve cells, fragments of Aβ stick together and form clumps that degrade the communications between neuron cells.  As the clumps […]

Groton Maze Learning Test Found To Be Accurate Indicator For Executive Function In Schizophrenia Patients

February 24, 2014

One of the brain’s most important roles is coordinating our daily life through an ongoing series of activities including decision making, planning, reasoning and problem solving. This collection of tasks, known as executive function, is called on when a new situation requires a novel response. It is often this set of cognitive abilities that breaks […]

Cogstate Researchers Find That CPAL Test Not Sensitive To Alzheimer’s Treatment

February 17, 2014

In the ongoing search for effective treatments for Alzheimer’s disease, medical researchers need to deal with the ever changing characteristics of each patient’s condition.  Finding a potential therapeutic during a clinical trial requires a cognition metric that can be sensitive to the daily cognitive fluctuations of each patient.  Designing, selecting and administering the right test […]

Demand Grows For Pediatric Cognition Safety Testing Using Cogstate System

February 12, 2014

It is a dilemma faced by parents, physicians and researchers. To find new treatments or medicines for sick children, these same kids often need to be part of clinical research trials. Pharmaceutical companies are required by regulators to collect data on children, and their challenge is to find ways to minimize the time and complexity […]

Gene Variant Linked To Memory Decline In Alzheimer’s Patients

February 3, 2014

As the search for the origins of Alzheimer’s disease intensifies, there is mounting evidence that our genes have a direct effect on our risk level.  While we can’t change our inherited gifts, new research that identifies specific genes may provide an advance warning system that can help us watch for early signs of cognitive decline. […]

1 2